RESEARCH PIPELINE
FNDR has generated a pipeline of therapeutics in various bacterial, viral, fungal and parasitic indications spanning over early-stage discovery to late-stage clinical trials.
TUBERCULOSIS
NONTUBERCULOUS MYCOBACTERIA
BACTERIAL INFECTIONS
FUNGAL INFECTIONS
MALARIA
INFLUENZA/COVID-19/RSV
DENGUE/ZIKA
PROJECT DETAILS
TBA-7371
Tuberculosis
Clinical Phase 2
A DprE1 inhibitor being developed for tuberculosis. The patent is jointly held by TB Alliance and FNDR. Phase 2 Clinical trial was successfully carried out by Gates Medical Research Institute in South Africa (Trial No. NCT04176250)
Chloroquine
Tuberculosis
Clinical Phase 2
A well-known clinical candidate repositioned for shortening TB therapy in partnership with Indian Institute of Science (IISc), Bangalore. Preclinical proof of concept studies and clinical trial (Phase 2) is funded by DBT India.
bacPROTACs
Tuberculosis
Hit to Lead
Homo-BacPROTACs are a novel class of compounds that target and degrade the essential protein ClpC1 in Mycobacterium tuberculosis. This targeted degradation mechanism shows potent antibacterial effects, including against multidrug-resistant tuberculosis strains.
FNDR-20364
NTM
Preclinical
A novel anti-TB compound extracted from the soil of Antarctica, has shown promising activity against drug resistant TB. FNDR is a patent holder along with National Centre for Polar and Ocean Research, Ministry of Earth Sciences, Government of India. It is also known as NF1001. FNDR-20364 has also shown excellent in vitro activity against multiple drug sensitive and drug resistant NTMs and its development for NTMs is funded by the Cystic Fibrosis Foundation (CFF), USA. FNDR-20364 also works against drug resistant Gram-postive bacteria.
Novel Series (Bacterial Infections)
Bacterial Infections
Hit to Lead
FNDR, ABAC Therapeutics Spain and Peptris Technologies have partnered to work on a first in class broad spectrum antibiotic working against Gram negative bacteria. This project is funded through an Indo-Spain Consortium grant by TDB India and CDTI Spain
Novel Series (Dengue/Zika)
Dengue
Hit to Lead
A novel class of compounds which works on all 4 serotypes of Dengue virus and Zika Virus. It is currently under Hit to lead stage and jointly being developed with National University of Singapore.
FNDR-20123
Malaria
Preclinical
A novel compound with novel mechanism which has shown excellent activity in vitro and in vivo against various malarial strains.
Device for Antibiotic Depletion from Waste Water Effluents
AMR
Validation
FNDR is developing a novel device made of waste materials to remove antibiotics from waste water. Antimicrobial resistance (AMR) is a global threat due to discharge/dumping of antibiotics from industries such as API manufacturing, poultry, fisheries, animal husbandry, and hospitals. Currently there is no device to deplete antibiotics from effluents. The lab scale device is ready and prototype device pilot studies have been completed. Proof of concept studies were funded by BIRAC India.
Biomarkers To Differentiate Bacterial Vs Viral Infections
AMR
Proof of Concept
FNDR is developing a blood-based diagnostic for rapid differentiation between bacterial and viral infections to guide antibiotic prescriptions . Antimicrobial resistance (AMR) is a global threat due to misuse of antibiotics. Pre-clinical validation has been completed. Project was funded by Longitude Prize, BIRAC-NESTA UK.
Biomarkers To Detect Tuberculosis
Tuberculosis
Proof of Concept
FNDR is developing a blood-based diagnostic for rapid detection of pulmonary and extra-pulmonary tuberculosis. Current biomarker-based tests for Pulmonary TB are low in accuracy or specificity. No tests exist for Extra-pulmonary TB. Clinical trial of 200 patients at St John’s Hospital, Bangalore has been completed to test for biomarkers in blood and urine. Data is promising and indicates potential for a rapid biomarker (blood) based diagnostic which can be converted to a Point of Care Test.